Aspire Biopharma Holdings (ASBP) Liabilities and Shareholders Equity (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $7.1 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 262.1% year-over-year to $7.1 million in Q1 2026; TTM through Mar 2026 was $11.8 million, a 31.63% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 786.66% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $7.1 million, up from $1.3 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for ASBP reached as high as $303.1 million in Q1 2023 and fell as low as $147989.0 in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $99.7 million across 5 years, with a median of $19.9 million in 2023.
• Across the five-year window, Liabilities and Shareholders Equity surged 102273.98% in 2022 and tumbled 99.26% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $300.2 million in 2022, then sank by 93.34% to $20.0 million in 2023, then tumbled by 99.26% to $147989.0 in 2024, then jumped by 786.66% to $1.3 million in 2025, then jumped by 442.4% to $7.1 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $7.1 million in Q1 2026, $1.3 million in Q4 2025, and $2.4 million in Q3 2025.